# Ozekibart PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/ozekibart

> The PDUFA target action date for ozekibart, sponsored by Inhibrx Biosciences, Inc. (INBX), is April 14, 2027. Status: scheduled.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### When is the ozekibart PDUFA date?

The PDUFA target action date for ozekibart, sponsored by Inhibrx Biosciences, Inc. (INBX), is April 14, 2027. Status: scheduled. Press release filed with the SEC (EX-99): "◦In June 2026, the U.S. Food and Drug Administration (FDA) accepted for filing the Company's biologics license application (BLA) for the potential approval of ozekibart in conventional chondrosarcoma and assigned a Prescription Drug User Fee Act (PDUFA) goal date of April 14, 2027." Last confirmed August 13, 2026. [Calendar and source filings](https://sec-api.dev/pdufa/ozekibart)

Source: Press release filed with the SEC (EX-99), accession 0002007919-26-000044, https://www.sec.gov/Archives/edgar/data/2007919/000200791926000044/exhibit99106302026.htm (retrieved 2026-11-12). Last confirmed 2026-08-13. Cite: https://sec-api.dev/pdufa/ozekibart#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | ozekibart |
| Codes | INBRX-109 |
| Sponsor | Inhibrx Biosciences, Inc. (INBX) https://sec-api.dev/companies/inbx/catalysts |
| Indications | with unresectable or metastatic conventional chondrosarcoma, metastatic or unresectable chondrosarcoma early, metastatic or unresectable chondrosarcoma, we may never, unresectable or metastatic conventional chondrosarcoma, advanced or metastatic, unresectable chondrosarcoma and, advanced or metastatic, unresectable chondrosarcoma |
| Modality |  |
| FDA designations | fast track, orphan |

## Timeline

### Oct 2025: interim data readout

- Status: scheduled. Date confidence: month.
- First seen 2025-08-13, last confirmed 2025-08-13.
- SEC Form 10-Q (accession 0002007919-25-000081): "Interim data on this cohort will be announced with the chondrosarcoma data, which are anticipated by late October 2025." https://www.sec.gov/Archives/edgar/data/2007919/000200791925000081/inhibrx-20250630.htm

### October 23, 2025: topline data readout

- Status: completed, positive. Date confidence: exact. Indication: advanced or metastatic, unresectable chondrosarcoma and.
- First seen 2025-10-23, last confirmed 2025-11-14.
- Press release filed with the SEC (EX-99) (accession 0002007919-25-000094): "On October 23, 2025, Inhibrx announced positive topline results from its registrational trial of ozekibart (INBRX-109) in chondrosarcoma and provided an update on its colorectal cancer and Ewing sarcoma expansion cohorts." https://www.sec.gov/Archives/edgar/data/2007919/000200791925000094/exhibit99109302025.htm
- SEC Form 8-K (accession 0002007919-25-000089): "On October 23, 2025, Inhibrx announced (i) positive topline results from its registrational ChonDRAgon study (n= 206) investigating ozekibart (INBRX-109) as a single agent versus placebo in patients with advanced or metastatic, unresectable chondrosarcoma and (ii) updates on the ongoing expansion cohorts investigating ozekibart in combination with FOLFIRI in late-line colorectal cancer and in combination with irinotecan and temozolomide in refractory Ewing sarcoma." https://www.sec.gov/Archives/edgar/data/2007919/000200791925000089/inhibrx-20251023.htm
- Press release filed with the SEC (EX-99) (accession 0002007919-25-000089): "SAN DIEGO, October 23, 2025 /PRNewswire/ - Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced positive topline results from the registrational ChonDRAgon study (n= 206) investigating ozekibart (INBRX-109) as a single agent versus placebo in patients with advanced or metastatic, unresectable chondrosarcoma." https://www.sec.gov/Archives/edgar/data/2007919/000200791925000089/exhibit991-pressreleaseoct.htm

### Q2 2026: NDA/BLA submission

- Status: scheduled. Date confidence: quarter. Indication: metastatic or unresectable chondrosarcoma early.
- First seen 2025-10-23, last confirmed 2026-03-19.
- Press release filed with the SEC (EX-99) (accession 0002007919-26-000007): "◦We expect to submit the Biologics License Application ("BLA") for ozekibart for the treatment of unresectable or metastatic conventional chondrosarcoma to the U.S. Food and Drug Administration ("FDA") early in the second quarter of 2026;" https://www.sec.gov/Archives/edgar/data/2007919/000200791926000007/exhibit99112312025.htm
- SEC Form 10-K (accession 0002007919-26-000006): "While we plan to submit a BLA to the FDA for the approval of ozekibart in patients with metastatic or unresectable chondrosarcoma early in the second quarter of 2026, there is no assurance that we will be successful in our efforts to submit a BLA on the timeline we expect or at all." https://www.sec.gov/Archives/edgar/data/2007919/000200791926000006/inbx-20251231.htm
- SEC Form 10-K (accession 0002007919-26-000006): "Our therapeutic candidates are still in clinical development and our emerging pipeline is still in preclinical development; although we plan to submit a BLA to the FDA early in the second quarter of 2026 for the approval of ozekibart in patients with metastatic or unresectable chondrosarcoma, we may never have an approved product that is commercially successful." https://www.sec.gov/Archives/edgar/data/2007919/000200791926000006/inbx-20251231.htm
- Press release filed with the SEC (EX-99) (accession 0002007919-25-000089): "-Inhibrx plans to file a BLA in Q2 of 2026" https://www.sec.gov/Archives/edgar/data/2007919/000200791925000089/exhibit991-pressreleaseoct.htm

### Apr 2026: NDA/BLA submission

- Status: completed. Date confidence: month.
- First seen 2026-05-14, last confirmed 2026-05-14.
- Press release filed with the SEC (EX-99) (accession 0002007919-26-000028): "◦Additionally, in April 2026, we submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ozekibart in conventional chondrosarcoma; and" https://www.sec.gov/Archives/edgar/data/2007919/000200791926000028/exhibit99103312026.htm

### June 15, 2026: NDA/BLA acceptance

- Status: completed. Date confidence: exact. Indication: with unresectable or metastatic conventional chondrosarcoma.
- First seen 2026-06-15, last confirmed 2026-08-13.
- SEC Form 8-K (accession 0002007919-26-000033): "On June 15, 2026, the Company announced that the FDA has accepted for filing its BLA seeking approval of ozekibart for the treatment of patients with unresectable or metastatic conventional chondrosarcoma." https://www.sec.gov/Archives/edgar/data/2007919/000200791926000033/inhibrx-20260615.htm
- Press release filed with the SEC (EX-99) (accession 0002007919-26-000044): "◦In June 2026, the U.S. Food and Drug Administration (FDA) accepted for filing the Company's biologics license application (BLA) for the potential approval of ozekibart in conventional chondrosarcoma and assigned a Prescription Drug User Fee Act (PDUFA) goal date of April 14, 2027." https://www.sec.gov/Archives/edgar/data/2007919/000200791926000044/exhibit99106302026.htm
- SEC Form 8-K (accession 0002007919-26-000033): "On June 15, 2026, Inhibrx Biosciences, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration (the "FDA") has accepted for filing its Biologics License Application (the "BLA") seeking approval of ozekibart (INBRX-109) for the treatment of patients with unresectable or metastatic conventional chondrosarcoma." https://www.sec.gov/Archives/edgar/data/2007919/000200791926000033/inhibrx-20260615.htm
- Press release filed with the SEC (EX-99) (accession 0002007919-26-000033): "SAN DIEGO, June 15, 2026/PRNewswire/ - Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its Biologics License Application (BLA) seeking approval of ozekibart (INBRX-109) for the treatment of patients with unresectable or metastatic conventional chondrosarcoma." https://www.sec.gov/Archives/edgar/data/2007919/000200791926000033/exhibit991-pressreleasebla.htm

### Q4 2026: trial start

- Status: scheduled. Date confidence: quarter.
- First seen 2026-04-21, last confirmed 2026-08-13.
- Press release filed with the SEC (EX-99) (accession 0002007919-26-000044): "◦The Company plans to meet with the FDA in the fourth quarter of 2026 to discuss plans to initiate a first-line registrational trial in CRC as well as the potential for an accelerated regulatory pathway for ozekibart in fourth-line CRC." https://www.sec.gov/Archives/edgar/data/2007919/000200791926000044/exhibit99106302026.htm
- SEC Form 10-Q (accession 0002007919-26-000042): "We plan to meet with the FDA in the fourth quarter of 2026 to discuss our plans to initiate a first-line registrational trial in CRC, as well as the potential for an accelerated regulatory pathway for ozekibart in fourth-line CRC." https://www.sec.gov/Archives/edgar/data/2007919/000200791926000042/inhibrx-20260630.htm
- SEC Form 10-Q (accession 0002007919-26-000027): "We plan to meet with the FDA in the second half of 2026 to discuss the potential for an accelerated regulatory pathway for ozekibart in fourth-line colorectal cancer and to discuss plans to initiate a first-line registrational trial in CRC." https://www.sec.gov/Archives/edgar/data/2007919/000200791926000027/inhibrx-20260331.htm
- Press release filed with the SEC (EX-99) (accession 0002007919-26-000028): "◦We plan to meet with the FDA in the second half of 2026 to discuss plans to initiate a first-line registrational trial in CRC." https://www.sec.gov/Archives/edgar/data/2007919/000200791926000028/exhibit99103312026.htm
- Press release filed with the SEC (EX-99) (accession 0002007919-26-000010): "Inhibrx plans to meet with the U.S. Food and Drug Administration (FDA) in the second half of 2026 to discuss plans to initiate a first-line registrational trial in CRC." https://www.sec.gov/Archives/edgar/data/2007919/000200791926000010/exhibit991-pressreleaseapr.htm
- SEC Form 8-K (accession 0002007919-26-000010): "Inhibrx plans to meet with the U.S. Food and Drug Administration ("FDA") in the second half of 2026 to discuss plans to initiate a first-line registrational trial in CRC." https://www.sec.gov/Archives/edgar/data/2007919/000200791926000010/inhibrx-20260421.htm

### Q1 2027: interim data readout

- Status: scheduled. Date confidence: quarter.
- First seen 2026-08-13, last confirmed 2026-11-13.
- Press release filed with the SEC (EX-99) (accession 0002007919-26-000044): "The Company expects to announce interim results from these cohorts during the first quarter of 2027." https://www.sec.gov/Archives/edgar/data/2007919/000200791926000044/exhibit99106302026.htm
- SEC Form 10-Q (accession 0002007919-26-000059): "We expect to announce interim results from these cohorts during the first quarter of 2027." https://www.sec.gov/Archives/edgar/data/2007919/000200791926000059/inhibrx-20260930.htm
- SEC Form 10-Q (accession 0002007919-26-000042): "We expect to announce interim results from these cohorts during the first quarter of 2027." https://www.sec.gov/Archives/edgar/data/2007919/000200791926000042/inhibrx-20260630.htm

### April 14, 2027: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2026-06-15, last confirmed 2026-08-13.
- Press release filed with the SEC (EX-99) (accession 0002007919-26-000044): "◦In June 2026, the U.S. Food and Drug Administration (FDA) accepted for filing the Company's biologics license application (BLA) for the potential approval of ozekibart in conventional chondrosarcoma and assigned a Prescription Drug User Fee Act (PDUFA) goal date of April 14, 2027." https://www.sec.gov/Archives/edgar/data/2007919/000200791926000044/exhibit99106302026.htm
- SEC Form 8-K (accession 0002007919-26-000033): "The FDA has not identified any filing review issues at this time and has assigned a PDUFA goal date of April 14, 2027." https://www.sec.gov/Archives/edgar/data/2007919/000200791926000033/inhibrx-20260615.htm
- Press release filed with the SEC (EX-99) (accession 0002007919-26-000033): "•No filing review issues identified by FDA with PDUFA goal date set for April 14, 2027" https://www.sec.gov/Archives/edgar/data/2007919/000200791926000033/exhibit991-pressreleasebla.htm
- Press release filed with the SEC (EX-99) (accession 0002007919-26-000033): "The FDA has not identified any filing review issues at this time and has assigned a Prescription Drug User Fee Act (PDUFA) goal date of April 14, 2027." https://www.sec.gov/Archives/edgar/data/2007919/000200791926000033/exhibit991-pressreleasebla.htm

Calendar months: [April 2027](https://sec-api.dev/fda-calendar/2027-04)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/ozekibart.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Ozekibart PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/ozekibart

```bibtex
@misc{secapidev_pdufa_ozekibart_20261116,
  title        = {Ozekibart PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/ozekibart}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_ozekibart_20261116","title":"Ozekibart PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/ozekibart","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
